& Pipeline


& Pipeline

ImmTAC molecules in action

Potent T cell redirection and cancer cell killing

The schematics below show how an ImmTAC molecule works. In the first step, ImmTAC molecules recognise and strongly bind to cancer cells displaying a particular target (peptide-HLA) (1). Circulating T cells are then recruited to the tumour site by interacting with the free end of the ImmTAC molecule (an anti-CD3 antibody fragment) (2). The ImmTAC molecule acts as a bridging molecule between the cancer cell and the T cell, enabling the formation of a perfectly optimised immune synapse (3). The redirected T cell is then activated and able to release its load of cancer cell killing lytic granules, leading to destruction of the cancer (4).





Visualising ImmTAC-redirected T cells in action

The videos below show real cancer cells being killed by ImmTAC-redirected T cells, the schematics on the right show the different cell types that can be seen in each video.

Here, ImmTAC-redirected non-cancer specific T cells (shown in blue) kill the cancer cells (shown in red), leaving adjacent non-cancerous cells (shown in green) intact.


Here, a single ImmTAC-redirected non-cancer specific T cell (shown in blue) kills multiple cancer cells (shown in red) through serial killing.